oxytocin and Postoperative-Nausea-and-Vomiting

oxytocin has been researched along with Postoperative-Nausea-and-Vomiting* in 5 studies

Reviews

1 review(s) available for oxytocin and Postoperative-Nausea-and-Vomiting

ArticleYear
Systematic review of oxytocin dosing at caesarean section.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:2

    We undertook a systematic review to determine the optimal dose of oxytocin after elective caesarean section or caesarean section in labouring women. We identified seven trials. These trials raise questions about the use of high dose (10 international units; IU) or moderate dose (5 IU) oxytocin in both settings and provide evidence that lower doses are equally effective but associated with significantly fewer side-effects. For elective caesarean section, a slow 0.3 to 1 IU bolus of oxytocin over one minute, followed by an infusion of 5 to 10 IU.h(-1) for four hours represents an evidence-based approach to dosing for women at low risk of postpartum haemorrhage. For the labouring parturient a slow 3 IU bolus of oxytocin, followed by an infusion of 5 to 10 IU.h(-1) for four hours is supported by limited evidence. These doses represent a starting point in the control of postpartum haemorrhage after caesarean section and do not reduce the need for mandatory active observation of the clinical situation, to detect situations that require additional doses of oxytocin or other uterotonic drugs. These doses of oxytocin minimise the risk of adverse haemodynamic changes as well as the unpleasant side-effect of nausea.

    Topics: Adult; Cesarean Section; Clinical Trials as Topic; Female; Hemodynamics; Humans; Oxytocics; Oxytocin; Postoperative Nausea and Vomiting; Postpartum Hemorrhage; Pregnancy

2012

Trials

3 trial(s) available for oxytocin and Postoperative-Nausea-and-Vomiting

ArticleYear
Adverse Effects of Carbetocin versus Oxytocin in the Prevention of Postpartum Haemorrhage after Caesarean Section: A Randomized Controlled Trial.
    Journal of pregnancy, 2018, Volume: 2018

    To compare the incidence of nausea, vomiting, and arterial hypotension between carbetocin and oxytocin to prevent haemorrhage after caesarean section (CS).. A randomized controlled trial in term pregnant women undergoing planned CS. Groups were randomized to carbetocin or oxytocin. Blood pressure (BP), heart rate, presence of nausea/vomitus, and need for vasopressors were evaluated throughout surgery. Preoperative and postoperative haemoglobin and haematocrit levels were compared.. Fifty-eight women were randomized (carbetocin. In planned CS, a possible clinical significant lower incidence of nausea after carbetocin was noted but this was not statistically significant. There were no differences regarding BP, heart rate, the need for vasopressor, and blood loss. The study was registered in the International Journal of Clinical Trials (ISRCTN 95504420, 2/2017).

    Topics: Adult; Blood Pressure; Cesarean Section; Female; Heart Rate; Humans; Oxytocics; Oxytocin; Postoperative Nausea and Vomiting; Postpartum Hemorrhage; Pregnancy

2018
Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section.
    British journal of anaesthesia, 2008, Volume: 101, Issue:6

    The optimal dose of oxytocin at Caesarean section is unclear. Oxytocin may cause adverse cardiovascular effects, including tachycardia and hypotension, whereas an inadequate dose can result in increased uterine bleeding. We compared the effects of two doses of oxytocin in a randomized double-blind trial.. Eighty patients undergoing elective Caesarean section received an i.v. bolus of either 2 or 5 units (u) of oxytocin after delivery, followed by an oxytocin infusion of 10 u h(-1). All received combined spinal-epidural anaesthesia with arterial pressure maintained by a phenylephrine infusion. We compared changes in heart rate (HR), mean arterial pressure (MAP), blood loss, uterine tone, the need for additional uterotonic drugs, and emetic symptoms.. There was a greater increase in mean (sd) HR in patients who received 5 u of oxytocin [32 (17) beats min(-1)] than in those who received 2 u [24 (13) beats min(-1)] (P=0.015). There was a larger decrease in MAP in patients who received 5 u [13 (15) mm Hg] than in those who received 2 u [6 (10) mm Hg] (P=0.030). The frequency of nausea and antiemetic use was higher after 5 u (32.5%) than 2 u (5%) (P=0.003). There were no differences in blood loss, uterine tone, or requests for additional uterotonic drugs (17.5% in both groups).. In elective Caesarean section, a 2 u bolus of oxytocin results in less haemodynamic change than 5 u, with less nausea and no difference in the need for additional uterotonics.

    Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Infusions, Intravenous; Muscle Tonus; Oxytocics; Oxytocin; Postoperative Care; Postoperative Nausea and Vomiting; Pregnancy; Uterus; Young Adult

2008
Efficacy and side effect profile of varying doses of intrathecal fentanyl added to bupivacaine for labor analgesia.
    International journal of obstetric anesthesia, 2004, Volume: 13, Issue:1

    The purpose of this randomized, double blinded and controlled study was to determine the optimal dose of intrathecal fentanyl when combined with bupivacaine 2.5 mg for initiation of labor analgesia. Parous parturients with cervical dilation between 3 and 5 cm were randomized to receive intrathecal fentanyl 0 (control), 5, 10, 15, 20 or 25 micrograms, combined with bupivacaine 2.5 mg, followed by a lidocaine/epinephrine epidural test dose. Visual analog pain scores (VAPS) and the presence of side effects were determined every 15 min until the parturient requested additional analgesia. Fetal heart rate (FHR) tracings were compared between groups. All parturients who received fentanyl >/= 15 micrograms had VAPS < 20 mm and duration of analgesia > 15 min, but this was not true for all parturients with fentanyl doses < 15 micrograms. Duration of analgesia was shorter for fentanyl groups 0, 5 and 10 micrograms, compared to groups 15, 20 and 25 micrograms, but there was no difference between the 15, 20 and 25 micrograms groups. There was no difference in the incidence of nausea and vomiting, or in FHR tracing changes. The incidence of pruritus was greater in all fentanyl groups compared to control. These data suggest that, when combined with intrathecal bupivacaine 2.5 mg, fentanyl 15 micrograms provides satisfactory analgesia to all parturients. Higher fentanyl doses produced no additional benefit in duration or quality of analgesia.

    Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fentanyl; Heart Rate, Fetal; Humans; Injections, Spinal; Oxytocin; Pain Measurement; Postoperative Nausea and Vomiting; Pregnancy; Pruritus

2004

Other Studies

1 other study(ies) available for oxytocin and Postoperative-Nausea-and-Vomiting

ArticleYear
The use of uterotonic drugs during caesarean section.
    International journal of obstetric anesthesia, 2010, Volume: 19, Issue:3

    The administration of oxytocic drugs during caesarean section is an important intervention to prevent uterine atony or treat established postpartum haemorrhage. Considerable past and current research has shown that these agents have a narrow therapeutic range. A detailed knowledge by anaesthetists of optimal doses and side effects is therefore required. Oxytocin remains the first line agent. In view of receptor desensitisation, second line agents may be required, namely ergot alkaloids and prostaglandins. This review examines the adverse haemodynamic and side effects, and methods for their limitation. An approach to dosing and choices of agent for the limitation of postpartum haemorrhage is suggested.

    Topics: Adult; Cesarean Section; Ergonovine; Ergot Alkaloids; Female; Humans; Oxytocics; Oxytocin; Postoperative Nausea and Vomiting; Pregnancy; Prostaglandins; Uterine Diseases; Uterine Inertia

2010